文献速递核素与放射性配体治疗肿瘤 PET/CT

226Ac作为诊疗一体化药物的临床前评估:显像、剂量学与治疗

Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy.
PubMed 文献 · J Nucl Med · 2024-11-01

本研究在AR42J肿瘤异种移植雄性NRG小鼠中评估了[226Ac]Ac-crown-TATE的诊疗一体化效能,SPECT/CT定量显像与离体生物分布一致,肿瘤5小时摄取>30%IA/g,估计平均吸收剂量系数为222 mGy/kBq。治疗组125、250、375 kBq使中位生存期从对照组的7天分别延长至16、24、27天,未观察到体重下降或毒性。

要点

  • [226Ac]Ac-crown-TATE的SPECT/CT定量显像与离体测量结果一致。
  • 肿瘤5小时摄取>30%IA/g,估计平均吸收剂量系数为222 mGy/kBq。
  • 125、250、375 kBq治疗组中位生存期分别为16、24、27天,对照组为7天。

核心结论

  • 本研究凸显了226Ac作为独立治疗同位素的诊疗一体化潜力,并展示了其评估匹配的225Ac放射性药物剂量学的诊断能力。
  • 未来研究将探究最大剂量与毒性,以进一步探索226Ac放射性药物的治疗潜力。

研究设计与样本

  • 概念验证性临床前研究,首次呈现226Ac靶向α治疗研究。
  • 226Ac在TRIUMF生产,与螯合剂-肽生物偶联物crown-TATE标记。
  • 使用携带AR42J肿瘤异种移植的雄性NRG小鼠,开展SPECT显像、生物分布与治疗研究。
  • 生物分布研究小鼠在注射后1、3、5、24、48小时安乐死,推导肿瘤与感兴趣器官的内照射剂量学。
  • 治疗研究小鼠分别给予125、250或375 kBq治疗,监测肿瘤大小与体况。

主要发现

  • 呈现了[226Ac]Ac-crown-TATE体内生物分布的定量SPECT图像,与离体测量结果一致。
  • 生物分布研究显示肿瘤高摄取(注射后5小时>30%IA/g)并滞留,估计平均吸收剂量系数为222 mGy/kBq。
  • [226Ac]Ac-crown-TATE治疗使中位生存期从对照组的7天显著延长至125、250、375 kBq治疗组的16、24、27天。
  • 生存期延长通过减缓肿瘤生长实现,未观察到体重下降或毒性。

关键数值与推荐

  • 肿瘤5小时摄取>30%IA/g,估计平均吸收剂量系数为222 mGy/kBq。
  • 对照组中位生存期7天,125 kBq组16天,250 kBq组24天,375 kBq组27天(各治疗组较对照组延长)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 本研究为概念验证性临床前研究。
  • 未来研究将探究最大剂量与毒性,以进一步探索226Ac放射性药物的治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

226Ac (t½ = 29.37 h) has been proposed as a theranostic radioisotope leveraging both its diagnostic γ-emissions and therapeutic α-emissions. 226Ac emits 158 and 230 keV γ-photons ideal for quantitative SPECT imaging and acts as an in vivo generator of 4 high-energy α-particles. Because of these nuclear decay properties, 226Ac has potential to act as a standalone theranostic isotope. In this proof-of-concept study, we evaluated a preclinical 226Ac-radiopharmaceutical for its theranostic efficacy and present the first 226Ac-targeted α-therapy study. Methods: 226Ac was produced at TRIUMF and labeled with the chelator-peptide bioconjugate crown-TATE. [226Ac]Ac-crown-TATE was selected to target neuroendocrine tumors in male NRG mice bearing AR42J tumor xenografts for SPECT imaging, biodistribution, and therapy studies. A preclinical SPECT/CT scanner acquired quantitative images reconstructed from both the 158 and the 230 keV emissions. Mice in the biodistribution study were euthanized at 1, 3, 5, 24, and 48 h after injection, and internal radiation dosimetry was derived for the tumor and organs of interest to establish appropriate therapeutic activity levels. Mice in the therapy study were administered 125, 250, or 375 kBq treatments and were monitored for tumor size and body condition. Results: We present quantitative SPECT images of the in vivo biodistribution of [226Ac]Ac-crown-TATE, which showed agreement with ex vivo measurements. Biodistribution studies demonstrated high uptake (>30%IA/g at 5 h after injection) and retention in the tumor, with an estimated mean absorbed dose coefficient of 222 mGy/kBq. [226Ac]Ac-crown-TATE treatments significantly extended the median survival from 7 d in the control groups to 16, 24, and 27 d in the 125, 250, and 375 kBq treatment groups, respectively. Survival was prolonged by slowing tumor growth, and no weight loss or toxicities were observed. Conclusion: This study highlights the theranostic potential of 226Ac as a standalone therapeutic isotope in addition to its demonstrated diagnostic capabilities to assess dosimetry in matched 225Ac-radiopharmaceuticals. Future studies will investigate maximum dose and toxicity to further explore the therapeutic potential of 226Ac-radiopharmaceuticals.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Koniar H, Wharton L, Ingham A, et al. Preclinical Evaluation of 226Ac as a Theranostic Agent: Imaging, Dosimetry, and Therapy. J Nucl Med. 2024. PMID: 39362766. doi:10.2967/jnumed.124.267999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。